Precision medicine firm SOPHiA GENETICS has announced the formation of a joint venture combining Memorial Sloan Kettering Cancer Center’s innovation in clinical diagnostics with its own AI platform to develop precision oncology treatments.
SOPHiA DDM, SOPHiA GENETICS's precision medicine platform, has been used to analyse more than 2.5 million cases since 2014, pioneering a unique, decentralised approach to precision oncology. MSK's in-house NGS program has sequenced more than 150,000 tumour samples since 2014, creating an extensive genomic dataset linked to clinical outcomes, pathology, and radiology records.
The memorandum of understanding (MOU) between the two organisations envisions a precision medicine hub that would combine MSK's clinical data and expertise with SOPHiA GENETICS's AI platform to unlock a new approach to multimodal precision oncology.
For patients, the proposed precision medicine hub will act as an incubation studio for the discoveries of tomorrow, equipped with a deployment platform to quickly deliver new capabilities to patients worldwide. The hub could move new discoveries from bench to clinical care faster than traditional models, expanding access to MSK's oncology intelligence for patients across the globe.
For biopharma partners, the hub could provide dedicated infrastructure for next-generation companion diagnostics, clinical algorithm development, and evidence generation.
The two institutions have a history of successful collaboration. Through previous license agreements involving MSK assays such as MSK-IMPACT and MSK-ACCESS, SOPHiA GENETICS has brought MSK diagnostics innovation to hospitals, laboratories, and patients in 35 countries across the globe using its SOPHiA DDM platform.
Although the specifics of this strategic initiative have yet to be finalised, it is envisioned that SOPHiA DDM would serve as the AI and analytics platform of the precision medicine hub, supporting its data, AI, and bioinformatics needs. MSK would contribute its clinical and scientific leadership, including support from its oncology faculty and exceptional ability to generate high-quality clinical data.
Ross Muken, President, SOPHiA GENETICS, said: "Our work with MSK has always been about extending the reach of MSK's clinical intelligence, and this joint venture is the most ambitious expression of that mission yet. Over the past several years, we've built SOPHiA DDM into a foundational AI and analytics layer for precision medicine, helping institutions across the world unlock the value of their clinical data. By combining MSK's clinical leadership and deep clinical data with SOPHiA GENETICS's AI platform and global infrastructure, the precision medicine hub that we are discussing will help move precision oncology into the multimodal era and bring the benefits of MSK's precision oncology to patients regardless of where they're treated."
Michael G Frank, Director of Digital Health Business Development at MSK, added: "This collaboration represents the future of applied precision oncology – where clinical expertise meets cutting-edge AI and robotics with the potential to transform cancer care at scale. By combining MSK's deep clinical assets with SOPHiA GENETICS's powerful digital platform, we're seeking to create a new paradigm to deliver personalised insights to patients."